The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone

@article{Lamberg1998TheEO,
  title={The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone},
  author={Tommi S. Lamberg and Kari T. Kivistö and Jouko Laitila and K M{\aa}rtensson and Pertti J. Neuvonen},
  journal={European Journal of Clinical Pharmacology},
  year={1998},
  volume={54},
  pages={761-766}
}
AbstractObjective: The effects of fluvoxamine, a selective serotonin (5-HT) reuptake inhibitor antidepressant, on the pharmacokinetics and pharmacodynamics of buspirone, a non-benzodiazepine anxiolytic agent, were investigated. Methods: In a randomized, placebo-controlled, two-phase cross-over study, ten healthy volunteers took either 100 mg fluvoxamine or matched placebo orally once daily for 5 days. On day 6, 10 mg buspirone was taken orally. Plasma concentrations of buspirone and its active… Expand
Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone
TLDR
Deramciclane does not inhibit CYP3A4 activity as measured by buspirone pharmacokinetics, and there were no indications of relevant pharmacodynamic interaction after multiple doses of deramcIClane and a single dose of buspir one. Expand
The Influence of Fluvoxamine Administration on Glibenclamide Pharmacokinetics After Multiple Oral Dosing in Rats
TLDR
Results indicated that following the single dose administration, glibenclamide C„, was 415±1 69ng/ml, T„„ was 3.7±1.4h, t, and fluvoxamine, a potent inhibitor of cytochrome P450 (CYP) isoenzymes may be coadministered with glibanclamide. Expand
Metabolism of Ramelteon in Human Liver Microsomes and Correlation with the Effect of Fluvoxamine on Ramelteon Pharmacokinetics
TLDR
In vitro metabolism data suggest that there may be a limit on the magnitude of DDI that can be estimated from in vitro data, and the example of the fluvoxamine-ramelteon DDI offers a unique example wherein one drug can simultaneously inhibit multiple enzymatic pathways of a second drug. Expand
Effects of cytochrome P450 (CYP) 3A4 inhibitors on the anxiolytic action of tandospirone in rat contextual conditioned fear
TLDR
Drugs with CYP3A4 inhibitory property may facilitate the anxiolytic effect of tandospirone when treating human anxiety disorders, in vivo. Expand
Pharmacokinetics of Haloperidol
AbstractHaloperidol is commonly used in the therapy of patients with acute and chronic schizophrenia. The enzymes involved in the biotransformation of haloperidol include cytochrome P450 (CYP),Expand
A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors
TLDR
Dovitinib should, therefore, not be co-administered with moderate and strong CYP1A2 inhibitors, without dose reduction, and patients are at risk of dovit inib related toxicity. Expand
Pharmacokinetic interaction between tandospirone and fluvoxamine in the rat contextual conditioned fear stress model and its functional consequence: Involvement of cytochrome P450 3A4
TLDR
The pharmacokinetic interaction between tandospirone and fluvoxamine is clarified and their combined effect in the rat anxiety model is evaluated. Expand
Hypnotics and sedatives
TLDR
A greater emphasis on objective, quantitative, and clinically relevant measures to assess the pharmacodynamic effects of these drugs is needed. Expand
Selective serotonin reuptake inhibitor drug interactions in patients receiving statins.
  • C. Andrade
  • Medicine
  • The Journal of clinical psychiatry
  • 2014
TLDR
Elderly patients commonly receive statin drugs for the primary or secondary prevention of cardiovascular and cerebrovascular events and SSRIs for the treatment of depression, anxiety, or other conditions, and a detailed literature review of statin metabolism and of SSRI effects on CYP enzymes suggests that escitalopram, citaloprams, and paroxetine are almost certain to be safe with all statins. Expand
Quantification of a cytochrome P450 3A4 substrate, buspirone, in human plasma by liquid chromatography-tandem mass spectrometry.
TLDR
A sensitive HPLC-tandem mass spectrometry method was developed and has been successfully applied to the analysis of buspirone levels in more than 500 human plasma samples collected from a drug interaction study. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 20 REFERENCES
The effect of chronic fluvoxamine on hormonal and psychological responses to buspirone in normal volunteers
TLDR
The blunting of GH and psychological responses suggest that 5-HT1A receptor function is reduced by chronic fluvoxamine treatment, which is likely to be due to inhibition of first pass liver metabolism by fluv oxamine acting on the cytochrome P-450 system. Expand
Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic.
TLDR
Although only wider clinical use for longer periods of time will more clearly define some elements of its pharmacological profile, with its low incidence of sedation buspirone is a useful addition to the treatments available for generalised anxiety. Expand
A Study of Pharmacokinetic Interaction Between Buspirone and Alprazolam at Steady State
TLDR
The results of this study suggest that coadministration of buspirone and alprazolam did not markedly affect the steady‐state pharmacokinetics of either drug. Expand
Metabolism and disposition of buspirone.
TLDR
The pharmacokinetics of buspirone were not significantly different in men and women or in individuals 21 to 40 years old compared with those over 65 years of age and co-administration of amitriptyline or diazepam did not alter the disposition of these agents or their demethylated metabolites. Expand
Metabolism of the antianxiety drug buspirone in human subjects.
TLDR
The metabolism of an oral dose of the antianxiety drug buspirone labeled with 14C/15N was studied in human subjects to facilitate structural characterization of the metabolites by mass spectrometry. Expand
Fluvoxamine is a potent inhibitor of cytochrome P4501A2.
TLDR
The present study demonstrates that fluvoxamine is a very potent inhibitor of the high-affinity O-deethylation of phenacetin, which is catalysed by cytochrome P4501A2 (CYP1A2), in microsomes from three human livers. Expand
Fluvoxamine. A review of global drug-drug interaction data.
TLDR
Clinical symptoms were infrequent and varied widely; no symptom clusters were identified; those agents metabolised by cytochrome P450 1A2 isoenzyme appear most likely to be involved in drug-drug interactions with fluvoxamine. Expand
In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo.
TLDR
Hepatocytes and phenobarbital- induced rat liver microsomes were better predictors of in vivo metabolism of buspirone than non-induced rat livermicrosomes and these in vitro systems should provide excellent models for studying the metabolism of other azaspirodecanedione-containing drugs. Expand
An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression.
TLDR
Clinical evidence is provided suggesting that buspirone augmentation may be a useful clinical alternative in depressed patients who fail to respond to a serotonin reuptake inhibitor. Expand
Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone
TLDR
This study investigated possible interactions of buspirone with verapamil and diltiazem to determine its first‐pass metabolism and found it potentially susceptible to drug interactions. Expand
...
1
2
...